Jiangsu Sinorda Biomedicine Co., Ltd
Quick facts
Phase 3 pipeline
- X842 · Diabetes
X842 is a small molecule that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Jiangsu Sinorda Biomedicine Co., Ltd portfolio CI brief
- Jiangsu Sinorda Biomedicine Co., Ltd pipeline updates RSS
Frequently asked questions about Jiangsu Sinorda Biomedicine Co., Ltd
What is Jiangsu Sinorda Biomedicine Co., Ltd's pipeline?
Jiangsu Sinorda Biomedicine Co., Ltd has 1 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include X842.
Related
- Sector hub: All tracked pharma companies